J&J, Bayer faces the first Xarelto jury trial over bleeding risks
More Info: Defective Drugs
The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be the initial indicator of whether juries are likely to side with the drugmakers, ruling that their med is safe and effective, or patients, who claim the two companies hid the real risks of the blood thinner.
The case in New Orleans was brought by Joseph Boudreaux, who took the drug to cut his stroke risk but claims it caused internal bleeding that caused heart problems and resulted in a visit to intensive care unit for a week, the Chicago Tribune reported.
In their defense, J&J and Bayer point out that the FDA has deemed the drug safe and effective and that the risks it holds are clearly laid out on its label.
See the full, original post here: https://www.fiercepharma.com/legal/j-j-bayer-face-first-jury-trial-over-blockbuster-xarelto-s-bleedings-risks
TriMark Legal Funding was founded in 2003 and is one of America's original lawsuit funding companies. TriMark provides pre-settlement loans and post-settlement loans to injured plaintiffs who are involved in personal injury lawsuits, employment litigation, work injury accidents and workers compensation settlement funding, mass tort litigation, and multidistrict litigation. We also provide loans for lawyers and law firm portfolio funding.
|Mass Torts||Other MDL|
Click here to see the original article.